FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015451788> ?p ?o ?g. }

• W2015451788 endingPage "2817" @default.
• W2015451788 startingPage "2808" @default.
• W2015451788 abstract "Abstract Purpose: The humanized anti-CD74 monoclonal antibody, milatuzumab, is in clinical evaluation for the therapy of multiple myeloma (MM). The ability of milatuzumab to increase the efficacy of bortezomib, doxorubicin, and dexamethasone was examined in three human CD74+ MM cell lines, CAG, KMS11, KMS12-PE, and one CD74-MM cell line, OPM-2. Experimental Design: Activity of milatuzumab as a monotherapy and combined with the drugs was evaluated by studying in vitro cytotoxicity, signaling and apoptotic pathways, and in vivo therapeutic activity in severe combined immunodeficient (SCID) mouse models of MM. Results: Given as a monotherapy, cross-linked milatuzumab, but not milatuzumab alone, yielded significant antiproliferative effects in CD74+ cells. The combination of cross-linked milatuzumab with bortezomib, doxorubicin, or dexamethasone caused more growth inhibition than either cross-linked milatuzumab or drug alone, producing significant reductions in the IC50 of the drugs when combined. Efficacy of combined treatments was accompanied by increased levels of apoptosis measured by increases of activated caspase-3 and hypodiploid DNA. Both milatuzumab and bortezomib affect the nuclear factor-κB pathway in CAG MM cells. In CAG- or KMS11-SCID xenograft models of disseminated MM, milatuzumab more than doubled median survival time, compared with up to a 33% increase in median survival with bortezomib but no significant benefit with doxorubicin. Moreover, combining milatuzumab and bortezomib increased survival significantly compared with either treatment alone. Conclusions: The therapeutic efficacies of bortezomib, doxorubicin, and dexamethasone are enhanced in MM cell lines when given in combination with milatuzumab, suggesting testing these combinations clinically." @default.
• W2015451788 created "2016-06-24" @default.
• W2015451788 creator A5003890903 @default.
• W2015451788 creator A5039370600 @default.
• W2015451788 creator A5047423264 @default.
• W2015451788 creator A5089854184 @default.
• W2015451788 creator A5091087285 @default.
• W2015451788 date "2009-04-15" @default.
• W2015451788 modified "2023-10-17" @default.
• W2015451788 title "Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines" @default.
• W2015451788 cites W147398146 @default.
• W2015451788 cites W1514197537 @default.
• W2015451788 cites W1558647085 @default.
• W2015451788 cites W1970654655 @default.
• W2015451788 cites W1979129905 @default.
• W2015451788 cites W1998434423 @default.
• W2015451788 cites W2015883486 @default.
• W2015451788 cites W2017407272 @default.
• W2015451788 cites W2038364325 @default.
• W2015451788 cites W2040598177 @default.
• W2015451788 cites W2050704142 @default.
• W2015451788 cites W2079111811 @default.
• W2015451788 cites W2102462570 @default.
• W2015451788 cites W2114918609 @default.
• W2015451788 cites W2127760782 @default.
• W2015451788 cites W2130781588 @default.
• W2015451788 cites W2136735139 @default.
• W2015451788 cites W2139156128 @default.
• W2015451788 cites W2139337843 @default.
• W2015451788 cites W2144621689 @default.
• W2015451788 cites W2155366350 @default.
• W2015451788 cites W2158470148 @default.
• W2015451788 cites W2158508282 @default.
• W2015451788 cites W2159680966 @default.
• W2015451788 cites W2161048718 @default.
• W2015451788 cites W2162002427 @default.
• W2015451788 cites W2168267840 @default.
• W2015451788 cites W2329072188 @default.
• W2015451788 cites W4237659442 @default.
• W2015451788 doi "https://doi.org/10.1158/1078-0432.ccr-08-1953" @default.
• W2015451788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2681251" @default.
• W2015451788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19351768" @default.
• W2015451788 hasPublicationYear "2009" @default.
• W2015451788 type Work @default.
• W2015451788 sameAs 2015451788 @default.
• W2015451788 citedByCount "47" @default.
• W2015451788 countsByYear W20154517882012 @default.
• W2015451788 countsByYear W20154517882013 @default.
• W2015451788 countsByYear W20154517882014 @default.
• W2015451788 countsByYear W20154517882015 @default.
• W2015451788 countsByYear W20154517882016 @default.
• W2015451788 countsByYear W20154517882017 @default.
• W2015451788 countsByYear W20154517882018 @default.
• W2015451788 countsByYear W20154517882019 @default.
• W2015451788 countsByYear W20154517882020 @default.
• W2015451788 countsByYear W20154517882021 @default.
• W2015451788 countsByYear W20154517882022 @default.
• W2015451788 countsByYear W20154517882023 @default.
• W2015451788 crossrefType "journal-article" @default.
• W2015451788 hasAuthorship W2015451788A5003890903 @default.
• W2015451788 hasAuthorship W2015451788A5039370600 @default.
• W2015451788 hasAuthorship W2015451788A5047423264 @default.
• W2015451788 hasAuthorship W2015451788A5089854184 @default.
• W2015451788 hasAuthorship W2015451788A5091087285 @default.
• W2015451788 hasBestOaLocation W20154517881 @default.
• W2015451788 hasConcept C126322002 @default.
• W2015451788 hasConcept C150903083 @default.
• W2015451788 hasConcept C185592680 @default.
• W2015451788 hasConcept C190283241 @default.
• W2015451788 hasConcept C203014093 @default.
• W2015451788 hasConcept C207001950 @default.
• W2015451788 hasConcept C2776364478 @default.
• W2015451788 hasConcept C2776694085 @default.
• W2015451788 hasConcept C2776999253 @default.
• W2015451788 hasConcept C2777478702 @default.
• W2015451788 hasConcept C2778367456 @default.
• W2015451788 hasConcept C2780401358 @default.
• W2015451788 hasConcept C2781303535 @default.
• W2015451788 hasConcept C502942594 @default.
• W2015451788 hasConcept C55493867 @default.
• W2015451788 hasConcept C71924100 @default.
• W2015451788 hasConcept C86803240 @default.
• W2015451788 hasConcept C98274493 @default.
• W2015451788 hasConceptScore W2015451788C126322002 @default.
• W2015451788 hasConceptScore W2015451788C150903083 @default.
• W2015451788 hasConceptScore W2015451788C185592680 @default.
• W2015451788 hasConceptScore W2015451788C190283241 @default.
• W2015451788 hasConceptScore W2015451788C203014093 @default.
• W2015451788 hasConceptScore W2015451788C207001950 @default.
• W2015451788 hasConceptScore W2015451788C2776364478 @default.
• W2015451788 hasConceptScore W2015451788C2776694085 @default.
• W2015451788 hasConceptScore W2015451788C2776999253 @default.
• W2015451788 hasConceptScore W2015451788C2777478702 @default.
• W2015451788 hasConceptScore W2015451788C2778367456 @default.
• W2015451788 hasConceptScore W2015451788C2780401358 @default.
• W2015451788 hasConceptScore W2015451788C2781303535 @default.
• W2015451788 hasConceptScore W2015451788C502942594 @default.
• W2015451788 hasConceptScore W2015451788C55493867 @default.

• next